Despite a recent 13% quarterly dip, Digital Turbine (NASDAQ: APPS) has delivered a staggering 116% return to investors over the past twelve months. This surge comes even as the mobile software company remains unprofitable, raising questions about the drivers behind its market optimism and its long-term trajectory.
After years of losses, London-listed Buccaneer Energy (LON:BUCE) is projected by analysts to turn its first profit in 2026, marking a potential turning point for the US-focused hydrocarbon explorer.
Royal Caribbean Cruises (RCL) shares surged nearly 19% after posting a 48% jump in annual profit, driven by robust ticket sales and onboard spending. The cruise giant's bullish outlook for 2026 signals continued strong demand in the travel sector.
Southwest Airlines capped off 2025 with record revenue and improved operations, positioning the carrier for what executives project will be a dramatic earnings acceleration next year, driven by new initiatives like assigned seating and a refined loyalty program.
Columbia Financial (NASDAQ: CLBK) reported fourth-quarter revenue that significantly exceeded Wall Street expectations, driven by a 247% year-over-year surge. The community bank's performance highlights strengthening net interest income and an accelerating tangible book value.
The professional staffing firm Kforce (NYSE:KFRC) reported fourth-quarter sales that edged past analyst expectations, yet its stock plunged 11.7% as earnings per share fell sharply short of estimates, highlighting ongoing challenges in a tightening labor market.
Capital Southwest Corporation (NASDAQ: CSWC) reported strong fourth-quarter revenue growth of 18.2%, surpassing Wall Street expectations. However, the business development company's GAAP earnings per share came in modestly below analyst consensus estimates.
The U.S. Space Development Agency's major contract award to Rocket Lab marks a pivotal expansion for the launch provider into the lucrative defense sector, with analysts forecasting accelerated revenue growth and a path to profitability.
Palantir Technologies smashed Wall Street expectations for Q4 2025, reporting a 70% surge in revenue and issuing guidance that signals even stronger growth ahead. The data analytics giant's performance underscores its deepening traction in both government and commercial sectors.
Life sciences and diagnostics firm Revvity (RVTY) closed 2025 with results surpassing internal targets, driven by robust diagnostics performance. While management provided initial 2026 guidance, it remains conservative, banking on market stabilization rather than a broad recovery.
Fourth-quarter earnings for S&P 500 companies are significantly outperforming expectations, led by robust growth in industrial and tech sectors, as investors await a busy week of corporate results and key economic data.
Meta Platforms' relentless investment in artificial intelligence infrastructure is set to drive capital expenditures to unprecedented levels in 2026, raising questions about long-term returns for the cash-rich tech giant.
Major financial institutions Barclays and Morgan Stanley maintain projections for two interest rate cuts in 2024, despite President Trump's nomination of inflation hawk Kevin Warsh to chair the Federal Reserve. Analysts suggest policy continuity in the near term, though Senate confirmation faces political hurdles.
The International Monetary Fund projects average growth in sub-Saharan Africa at 4.6% for the year, edging ahead of Asia's 4.1%, signaling a potential turning point driven by demographics but tempered by significant investment challenges.
Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.
The off-price retail giant TJX Companies is demonstrating remarkable capital efficiency, with its return on capital employed (ROCE) soaring to 31%—far outpacing industry averages—even without significant increases in capital investment over the past five years.
The alternative investment manager faces heightened scrutiny as analysts project a slowdown in revenue growth ahead of Tuesday's earnings release, despite a history of recent beats.
Graco Inc. delivered solid fourth-quarter results, meeting analyst forecasts with 8% sales growth driven by acquisitions and stable core demand. While management expressed confidence in integration efforts and margin initiatives, analysts on the earnings call pressed for details on long-term profitability and market headwinds.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
